no randomized trial of adoptive cell transfer techniques using either lymphokine-activated killer cells or tumour-infiltrating lymphocytes has demonstrated a statistically significant survival benefit over that seen with interleukin 2 (il-2) alone 8–10;. Here, IL2 is linked to neoplasm.